Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T17:32:26.497Z.
Calculation as of: 2026-10-06T17:32:26.497Z.
Quote observation: 2026-10-06T17:30:10.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f23401f377ae0c42cb4058dfce1620411e9c781823cb8ffdb9eedba1333334c1
PE RATIO
N/A
Market Cap
$5.89B
PE Ratio
31.43
TTM Avg
54.86
3Y Avg
51.97
5Y Avg
46.21
Market Cap
$5.74B
PE Ratio
76.86
TTM Avg
136.52
3Y Avg
215.24
5Y Avg
141.48
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Iovance Biotherapeutics, Inc. (IOVA) | $5.90B | N/A | N/A | N/A | N/A |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $5.89B | 31.43 | 54.86 | 51.97 | 46.21 |
| GRAIL Inc. (GRAL)vs › | $5.99B | N/A | N/A | N/A | N/A |
| Kodiak Sciences Inc. (KOD)vs › | $5.77B | N/A | N/A | N/A | N/A |
| Kiniksa Pharmaceuticals International, plc (KNSA)vs › | $5.74B | 76.86 | 136.52 | 215.24 | 141.48 |
| Rhythm Pharmaceuticals, Inc. (RYTM)vs › | $6.18B | N/A | N/A | N/A | N/A |
| CG Oncology Inc. (CGON)vs › | $5.61B | N/A | N/A | N/A | N/A |
| RadNet, Inc. (RDNT)vs › | $5.53B | N/A | 670.99 | 322.02 | 261.00 |
| MiniMed Group, Inc. Common Stock (MMED)vs › | $5.49B | N/A | N/A | N/A | N/A |
| Amneal Pharmaceuticals, Inc. (AMRX)vs › | $6.48B | 41.65 | 449.70 | 488.80 | 367.50 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$13.22
Forward EPS (Est.)
$-0.45
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
